PTC Therapeutics (FRA:BH3) Cyclically Adjusted Revenue per Share: €8.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €67.74
GF Value €32.46
! 8 Warning Signs
View Full Analysis

What is PTC Therapeutics Cyclically Adjusted Revenue per Share?

PTC Therapeutics FRA:BH3 +0.53% 51 Cyclically Adjusted Revenue per Share is €8.24 as of Mar. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €32.46. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PTC Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €2.857. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.24 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PTC Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 12.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PTC Therapeutics was 21.40% per year. The lowest was 20.80% per year. And the median was 21.10% per year.

As of today (2026-07-26), PTC Therapeutics's current stock price is €67.74. PTC Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €8.24. PTC Therapeutics's Cyclically Adjusted PS Ratio of today is 8.22.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PTC Therapeutics was 11.11. The lowest was 3.11. And the median was 7.06.


PTC Therapeutics  (FRA:BH3) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PTC Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=67.74/8.24
=8.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PTC Therapeutics was 11.11. The lowest was 3.11. And the median was 7.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PTC Therapeutics Cyclically Adjusted Revenue per Share Related Terms


PTC Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Cyclically Adjusted Revenue per Share Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.74 4.79 5.81 7.04 8.08

PTC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.55 7.90 7.81 8.08 8.24

FRA:BH3 vs SRRK, COGT, RYTM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PTC Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.857/330.2130*330.2130
=2.857

Current CPI (Mar. 2026) = 330.2130.

PTC Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.409 241.018 0.560
201609 0.601 241.428 0.822
201612 0.699 241.432 0.956
201703 0.724 243.801 0.981
201706 1.077 244.955 1.452
201709 0.850 246.819 1.137
201712 1.591 246.524 2.131
201803 1.092 249.554 1.445
201806 1.275 251.989 1.671
201809 0.955 252.439 1.249
201812 1.507 251.233 1.981
201903 0.849 254.202 1.103
201906 1.354 256.143 1.746
201909 1.148 256.759 1.476
201912 1.399 256.974 1.798
202003 0.990 258.115 1.267
202006 1.025 257.797 1.313
202009 1.486 260.280 1.885
202012 1.418 260.474 1.798
202103 1.411 264.877 1.759
202106 1.375 271.696 1.671
202109 1.671 274.310 2.012
202112 2.069 278.802 2.451
202203 1.896 287.504 2.178
202206 2.194 296.311 2.445
202209 3.060 296.808 3.404
202212 2.175 296.797 2.420
202303 2.792 301.836 3.054
202306 2.641 305.109 2.858
202309 2.444 307.789 2.622
202312 3.730 306.746 4.015
202403 2.527 312.332 2.672
202406 2.261 314.175 2.376
202409 2.305 315.301 2.414
202412 2.636 315.605 2.758
202503 12.593 319.799 13.003
202506 1.984 322.561 2.031
202509 2.064 324.800 2.098
202512 1.520 324.054 1.549
202603 2.857 330.213 2.857

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €8.24 mean?
PTC Therapeutics (FRA:BH3) has a Cyclically Adjusted Revenue per Share of €8.24 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Cyclically Adjusted Revenue per Share too high?
PTC Therapeutics' current Cyclically Adjusted Revenue per Share is €8.24. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Cyclically Adjusted Revenue per Share compare to SRRK and COGT?
PTC Therapeutics' Cyclically Adjusted Revenue per Share of €8.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Cyclically Adjusted Revenue per Share is €8.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Cyclically Adjusted Revenue per Share of €8.24. The stock's GF Value™ is €32.46, compared to a current price of €67.74 — trading 108.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €8.24. PTC Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Cyclically Adjusted Revenue per Share is €8.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €67.74 is trading 108.7% above its estimated GF Value™ of €32.46.

Key valuation signals for FRA:BH3:

  • Cyclically Adjusted Revenue per Share: €8.24
  • GF Value™: €32.46 vs. price of €67.74 (108.7% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.74
Price
€32.46
GF Value